2023 Targeted Therapies of Lung Cancer Meeting (Poster)-P1.21. HER2/ERBB2 Mutations in Metastatic Non-Small Cell Lung Cancer – Prevalence, Real-World Treatment Patterns and Outcomes from a Clinico-Genomic Database

P1.21. HER2/ERBB2 Mutations in Metastatic Non-Small Cell Lung Cancer – Prevalence, Real-World Treatment Patterns and Outcomes from a Clinico-Genomic Database

Back to course

Pdf Summary

This study aimed to assess the frequency of HER2 mutations, treatment patterns, and outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) in a real-world setting. The study used medical records from 164 patients with HER2-mutant mNSCLC in the Flatiron Clinico-Genomic database.<br /><br />The findings showed that the frequency of HER2 mutations in mNSCLC was consistent with previous reports, at approximately 2%. Most patients with HER2-mutant mNSCLC received platinum-based chemotherapy or chemotherapy immunotherapy as their first-line treatment, with HER2-targeted therapies being used in later lines of treatment. Over half of the patients progressed within 6 months of starting first-line treatment, highlighting the need for more effective therapies for this oncogenic driver.<br /><br />The study also had some limitations, including unconfirmed HER2 mutation test results and a limited sample size of patients treated with newly approved HER2-targeted therapies. However, the study suggested that HER2 testing prior to the first line of therapy could improve the adoption of HER2-targeted therapy in mNSCLC.<br /><br />Overall, the study found that HER2 mutations in mNSCLC are rare but actionable oncogenic alterations. More effective treatments are needed to improve the survival of patients with HER2-mutant mNSCLC. Future studies with larger cohorts should further investigate the effectiveness of different HER2-targeted therapies in a real-world setting.

Asset Subtitle

Sarah Waliany, Stanford University School of Medicine, United States

Meta Tag

Speaker Sarah Waliany, Stanford University School of Medicine, United States

Topic Poster Listing

Keywords

HER2 mutations

metastatic non-small cell lung cancer

treatment patterns

outcomes

real-world setting

medical records

Flatiron Clinico-Genomic database

platinum-based chemotherapy

chemotherapy immunotherapy

HER2-targeted therapies